PAVmed (PAVM) majority-owned subsidiary Lucid Diagnostics to spin-off into separate public company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results
February 22, 2021 8:18 AM ESTAnnounces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company
Lucid Diagnostics to launch major new multi-channel commercialization initiative for its EsoGuard Esophageal DNA Test
Conference call to be held today at 8:30 AM EST
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Lucid) and Solys Diagnostics Inc. (Solys), discussed preliminary financial results for the... More
